Skip Navigation



Hum. Reprod. Advance Access published online on February 24, 2006
Human Reproduction, doi:10.1093/humrep/dei505
This Article
Right arrow FREE Full Text (PDF ) Freely available
Right arrow All Versions of this Article:
21/6/1400    most recent
dei505v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Rautio, K.
Right arrow Articles by Morin-papunen, L.C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rautio, K.
Right arrow Articles by Morin-papunen, L.C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
Received October 19, 2005
Revised December 13, 2005
Accepted December 21, 2005

Article

Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: a randomized placebo-controlled study

K. Rautio 1, J.S. Tapanainen 1 *, A. Ruokonen 2, and L.C. Morin-papunen 1

1 Department of Obstetrics and Gynaecology, Oulu University Hospital, Oulu, Finland
2 Department of Clinical Chemistry, Oulu University Hospital, Oulu, Finland

* To whom correspondence should be addressed.
J.S. Tapanainen, E-mail: juha.tapanainen{at}oulu.fi


  Abstract

BACKGROUND: The objective of the study was to assess the therapeutic effects of rosiglitazone in overweight women with polycystic ovary syndrome (PCOS). METHODS: A double-blind, placebo-controlled study was conducted on 30 (BMI > 25 kg/m2, mean age 29.1 ± 1.2 years) overweight women with PCOS treated with rosiglitazone or placebo for 4 months. Waist-to-hip ratios (WHRs), serum concentrations of sex hormones and binding proteins, blood glucose, serum insulin and serum C-peptide during a 75-g oral glucose tolerance test (OGTT), first-phase insulin secretion as determined by an intravenous glucose tolerance test (IVGTT), M values (expressing insulin sensitivity using a eug-lycaemic clamp) and calorimetric data were assessed at 0 and 4 months of treatment. RESULTS: Rosiglitazone improved menstrual cyclicity, increased serum sex hormone-binding globulin (SHBG) levels and decreased serum levels of androstenedione, 17-hydroxyprogesterone (17-OHP), dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulphate (DHEA-S). Glucose tolerance [expressed as AUCglucose during the OGTT] improved (P = 0.002) and peripheral insulin response (expressed as AUCinsulin decreased (P = 0.004) in the rosiglitazone group (ROSI group). M value improved in the ROSI group from 33.4 ± 3.27 to 40.0 ± 5.51 µmol/kg min (P = 0.04). CONCLUSION: Rosiglitazone, by improving menstrual cyclicity, hyperandrogenism, insulin resistance and hyperinsulinaemia, represents an alternative treatment for overweight anovulatory women with PCOS and no pregnancy desire.

Keywords: insulin resistance/PCOS/rosiglitazone.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
J. Puurunen, T. Piltonen, P. Jaakkola, A. Ruokonen, L. Morin-Papunen, and J. S. Tapanainen
Adrenal Androgen Production Capacity Remains High up to Menopause in Women with Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab., June 1, 2009; 94(6): 1973 - 1978.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
D. M. Selva and G. L. Hammond
Peroxisome-Proliferator Receptor {gamma} Represses Hepatic Sex Hormone-Binding Globulin Expression
Endocrinology, May 1, 2009; 150(5): 2183 - 2189.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
M. Jensterle, M. Sebestjen, A. Janez, J. Prezelj, T. Kocjan, I. Keber, and M. Pfeifer
Improvement of endothelial function with metformin and rosiglitazone treatment in women with polycystic ovary syndrome
Eur. J. Endocrinol., October 1, 2008; 159(4): 399 - 406.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
M. Jensterle, A. Janez, B. Mlinar, J. Marc, J. Prezelj, and M. Pfeifer
Impact of metformin and rosiglitazone treatment on glucose transporter 4 mRNA expression in women with polycystic ovary syndrome.
Eur. J. Endocrinol., June 1, 2008; 158(6): 793 - 801.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. C. Vantyghem, D. Vincent-Desplanques, F. Defrance-Faivre, J. Capeau, C. Fermon, A. S. Valat, O. Lascols, A. C. Hecart, P. Pigny, B. Delemer, et al.
Fertility and Obstetrical Complications in Women with LMNA-Related Familial Partial Lipodystrophy
J. Clin. Endocrinol. Metab., June 1, 2008; 93(6): 2223 - 2229.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
J. E. Nestler
Metformin for the Treatment of the Polycystic Ovary Syndrome
N. Engl. J. Med., January 3, 2008; 358(1): 47 - 54.
[Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
A Majuri, M Santaniemi, K Rautio, A Kunnari, J Vartiainen, A Ruokonen, Y A Kesaniemi, J S Tapanainen, O Ukkola, and L Morin-Papunen
Rosiglitazone treatment increases plasma levels of adiponectin and decreases levels of resistin in overweight women with PCOS: a randomized placebo-controlled study
Eur. J. Endocrinol., February 1, 2007; 156(2): 263 - 269.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.